Four more biotechnology companies are set to go public this Thursday. Details for these IPOs are listed below. The details and times of IPOs are subject to change.
Ascendis Pharma A/S (NASDAQ: ASND) is a biotech company developing improved versions of existing drugs. The company's proprietary platform is called TransCon.
The company is testing drugs using TransCon for Pediatric Growth Hormone Deficiency, Adult Growth Hormone Deficiency, Pulmonary Arterial Hypertension, Diabetes, and Opthalmology.
On December 15, Ascendis announced positive six-month interim results from a Phase 2 Pediatric Study for the treatment of Growth Hormone Deficiency. The company expects to release top-line data in the middle of 2015.
Related Link: 3 Biotech IPOs Debuting This Week
Ascendis is offering 5 million shares, and the underwriters are Bank of America Merrill Lynch, Leerink Partners, and Wells Fargo.
The price range is $16 to $18 and the market cap at the middle of the range is $372 million. The deal was expected to price Wednesday night and trade Thursday, but has been accelerated to price Tuesday night and trade Wednesday.
EyeGate Pharmaceuticals (NASDAQ: EYEG) is a biotechnology company focused on developing a drug delivery system for treating diseases of the eye. The company's lead product is EGP-437. The EyeGate II Delivery system is non-invasive and is being tested in Anterior Uveitis, Dry Eye, and Cataract Surgery.
EyeGate is offering 1.43 million shares and the underwriters are Aegis Capital and Chardan.
The price range is $6 to $8, and the market cap at the middle of the range is $48.3 million. The deal is expected to price Wednesday night and trade Thursday.
Entellus Medical (NASDAQ: ENTL) is a medical device company developing minimally invasive products for chronic sinusitis. According to clinical trials, Entellus products are as effective as functional endoscopic sinus surgery, but patients experience less discharge and a faster recovery.
Although not yet profitable, the company is gaining traction with $45.1 million in revenues over the last 12 months.
The company is offering 4.38 million shares and the underwriters are Bank of America Merrill Lynch, Piper Jaffray, Blair, and Canaccord Genuity.
The price range is $15 to $17, and the market cap at the middle of the range is $278 million. The deal is expected to price Wednesday night and trade Thursday.
Flex Pharma (NASDAQ: FLKS) is also set to debut Thursday. Details for that deal can be found here.
See more from Benzinga
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.